Clinical Trial Update: A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy. [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating Mircera given every two weeks for dialysis patients with chronic renal anemia not previously treated with ESAs has completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 4 | Status: COMPLETED | Results posted: 2016-06-02